Cortexyme racks up $76 mln Series B
South San Francisco-based Cortexyme Inc, a developer of drugs focused on treating Alzheimer’s disease and other degenerative diseases, has closed $76 million in Series B funding. The investors included Sequoia Capital, Vulcan Capital, Verily Life Sciences, EPIQ Capital Group, RSL Investments, Huizenga Capital, Pfizer, Takeda Ventures, Lamond Family, Breakout Ventures and Dolby Family Ventures.
31 May 2018•1 min read
